Attovia Therapeutics, Inc. - 8-K Filing

Attovia Therapeutics reports Q3 2026 results and positive Phase 1b topline data for ATTO-1310, projecting cash runway into 2030. (Items: 2.02 Results of Operations and Financial Condition, 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $ATTO

Read the full article at SEC EDGAR

More Regulatory news